9008 H13 Xentec LED 6500K Beam Low High F150 Ford for Kit Bulbs Headlight Car & Truck LED Light Bulbs


  1. Home
  2. 9008 H13 Xentec LED 6500K Beam Low High F150 Ford for Kit Bulbs Headlight
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Xentec H13 9008 LED Headlight Bulbs Kit for Ford F150 High Low Beam 6500K
Condition: New Brand:

XENTEC

Output Lumen: True 12000 LMs Combined Output/16000 LMs for Hi/lo Manufacturer Part Number:

XTB2RED-H13-W-0090

Lifespan: 50,000 Hours Wattage: 256 Watts Combined
Kit Content: 2 Bulbs 2 Drivers 1 Manual Waterproof Rating: IP68
Color Output: 6000K Hyper White Heat Control: Variable Speed Fan Module (VSFM) 12000RPM TurboFan
Bulb Size: H4/9003/HB2











published on tue nov 09 2021

9008 H13 Xentec LED 6500K Beam Low High F150 Ford for Kit Bulbs Headlight Car & Truck LED Light Bulbs

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

9008 H13 Xentec LED 6500K Beam Low High F150 Ford for Kit Bulbs Headlight Car & Truck LED Light Bulbs

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS